BNP Paribas reissued their neutral rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Wednesday morning. The brokerage currently has a GBX 5,300 ($66.02) price objective on the biopharmaceutical company’s stock.
Other research analysts have also issued research reports about the company. Deutsche Bank AG reaffirmed a buy rating and set a GBX 6,000 ($74.74) target price on shares of AstraZeneca plc in a report on Wednesday, November 30th. Shore Capital downgraded AstraZeneca plc to a sell rating and set a GBX 4,000 ($49.83) price target for the company. in a research report on Monday, February 6th. J P Morgan Chase & Co reiterated a neutral rating and set a GBX 4,600 ($57.30) price target on shares of AstraZeneca plc in a research report on Tuesday, December 6th. Credit Suisse Group reiterated an underperform rating and set a GBX 4,000 ($49.83) price target on shares of AstraZeneca plc in a research report on Friday, February 3rd. Finally, Bryan, Garnier & Co reiterated a buy rating and set a GBX 5,250 ($65.40) price target on shares of AstraZeneca plc in a research report on Monday, January 9th. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of GBX 4,910.86 ($61.17).
Shares of AstraZeneca plc (LON:AZN) opened at 4623.0210 on Wednesday. The firm’s 50-day moving average is GBX 4,429.89 and its 200-day moving average is GBX 4,666.07. The firm’s market cap is GBX 58.48 billion. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.
WARNING: This piece of content was reported by sleekmoney and is the sole property of of sleekmoney. If you are accessing this piece of content on another domain, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at http://sleekmoney.com/bnp-paribas-reaffirms-neutral-rating-for-astrazeneca-plc-azn-2/1657199.html.
The business also recently announced a dividend, which will be paid on Monday, March 20th. Shareholders of record on Thursday, February 16th will be issued a GBX 150.20 ($1.87) dividend. This represents a yield of 3.52%. This is an increase from AstraZeneca plc’s previous dividend of $68.70. The ex-dividend date of this dividend is Thursday, February 16th.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/bnp-paribas-reaffirms-neutral-rating-for-astrazeneca-plc-azn-2/1657199.html
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.